Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study

Séverine Vermeire, Silvio Danese, Wen Zhou, Dapo Ilo, Justin Klaff, Gweneth Levy, Xuan Yao, Su Chen, Yuri Sanchez Gonzalez, Xavier Hébuterne, James O. Lindsay, Peter D.R. Higgins, Qian Cao, Hiroshi Nakase, Jean Frédéric Colombel, Edward V. Loftus, Remo Panaccione

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study'. Together they form a unique fingerprint.

Medicine & Life Sciences